


## IBT6A

<b>Cat. No.:</b>	HY-13036A		
<b>CAS No.:</b>	1022150-12-4		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>22</sub> N <sub>6</sub> O		
<b>Molecular Weight:</b>	386.45		
<b>Target:</b>	Btk		
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## BIOLOGICAL ACTIVITY

<b>Description</b>	IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct <sup>[1]</sup> . Ibrutinib is a selective, irreversible Btk inhibitor with an IC <sub>50</sub> of 0.5 nM <sup>[2]</sup> .
<b>In Vitro</b>	IBT6A (Compound 14) can be used in synthesis of Ibrutinib and Ibrutinib-based activity-based probes (ABPs) <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. *Org Biomol Chem*. 2015 May 14;13(18):5147-57.
- [2]. Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES.
- [3]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci U S A*. 2010 Jul 20;107(29):13075-80.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA